Analysts Stocks

      Daily Update - Jan 09, 2023

      Selected highlights of the day

      By: Matthew Otto

      Saia sees mixed reviews

      • Morgan Stanley analyst Ravi Shanker gave Saia the thumbs up, upgrading his rating from Underweight to Equal-Weight and setting a price target at $185.
      • Susquehanna analyst Bascome Majors switched his outlook from Positive to Neutral

       

       Coinbase receives mixed reviews from Wall Street analysts

      • Trevor Williams of Jefferies initiated coverage with a Hold rating and $35 price target.
      • Will Nance of Goldman Sachs maintained his Sell rating and lowered the price to $30.
      • Devin Ryan at JMP Securities kept his Market Outperform title while lowering the price target down to $80
      •  Jeff Cantwell from Wells Fargo stayed with Underweight and revised his prediction further downwards from  $55 to $33.

       

      Square purchase of  Afterpay is under scrutiny

      Johnson Fistel  is conducting an investigation into Block Inc.’s acquisition of Afterpay to determine whether its officers and other individuals violated securities laws with their mismanagement or failure to timely disclose important information.

      • Jeff Cantwell from Wells Fargo has maintained an ‘Overweight’ rating for the stock but lowered his price target slightly from $97 down to $96.

      Carnival and PayPal catch cold wind but not Visa

      • UBS analyst Robin Farley adjusted their outlook on Carnival Corp. from a Buy to a Hold, and downgraded the stock’s price target by 25%, from $16 to $12.
      • Josh Beck of Keybanc has reduced his view on PayPal Holdings, lowering from Overweight rating to  Sector Weight for the first time since taking cover in 2017.
      • Beck has also given Visa an upgrade to Overweight and a $210 price target.

       

      Silvergate Capital’s stock has been experiencing a tumultuous period

      • Manan Gosalia of Morgan and David Chiaverini of Wedbush decreased them from $24-$15 range all the way down to $1-$9.
      • Goldman Sachs Will Nance maintained his rating as Neutral while slashing his price target from $35 to $10.

      With the deadline looming, Securities Litigation Partner James (Josh) Wilson is encouraging Silvergate investors who experienced losses of $100K or more to contact him.

      CB

      • Jefferies analyst Yaron Kinar has readjusted his outlook on Chubb, lowering the rating from Buy to Hold and increasing his price target for investors from $241 to $246. Since 2018, Kinar has kept his stock forecast above the stock price.

       

      • BAML Analyst John Murphy gave Adient the thumbs up, upgrading it to a Buy and raising his price target from $41 to $52. Murphy navigated the unpredictable tides of 2020 with great prowess, unerringly predicting a downturn for ADNT stock and maintaining his confident outlook.

       

      DAWN is having a bright day

      Day One announced they had promising topline data from Phase 2 FireFly-1 trial of Tovorafenib (DAY101) in recurrent Pediatric Low-Grade Glioma patients – showing a 64% response rate with 91% benefit amongst 69 heavily pretreated RANO evaluable subjects.

      Median duration was 8.4 months as of September 28th 2022 with 77%, that’s almost 4 out 5., still receiving treatment at that time. More exciting news will be presented soon at an upcoming medical conference during Q2 2021 so get ready investors, DAWN might soar even higher before we know it..

       

      • Andrea Tan raised her stock forecast from $45 to $62 while maintaining a Buy rating.
      • Joseph Catanzaro boosting his price target from $40 to 45 whilst upholding an Overweight outlook.
      • Andres Maldonado adjusted the mark upwards to $45 with keeping his Buy rating.